In spite of the progress made in the development of KRAS inhibitors, there is still continued interest to develop inhibitors of other KRAS such as KRAS for the treatment of diseases, including prostate cancer, colorectal cancer, and non-small-cell lung cancer. This Patent Highlight provides exemplary compounds having activity as inhibitors of G12D mutant KRAS protein.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10107906 | PMC |
| http://dx.doi.org/10.1021/acsmedchemlett.3c00076 | DOI Listing |
Publication Analysis
Top Keywords
prostate cancer
8
kras
5
targeting "undruggable"
4
"undruggable" driver
4
driver protein
4
protein kras
4
kras potential
4
potential therapy
4
therapy prostate
4
cancer
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!